CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
CeriBell, Inc. reports a Schedule 13G/A filing by The Global Value Investment Portfolio Management Pte Ltd and affiliated reporting persons.
The filing states beneficial ownership of 1,572,146 shares of Common Stock, equal to 4.2% of the class based on 37,859,680 shares outstanding as of March 31, 2026. The shares are held by u.life fund and none are held by GVIP Ventures SPC-SP3. The filing attributes shared voting and shared dispositive power of 1,572,146 shares to the reporting persons through The Global Value Investment Portfolio Management Pte Ltd and notes Caroline Kwong as Managing Director. Signature dates appear as May 14, 2026.
CeriBell, Inc. reported beneficial ownership information for Xingjuan Chao as of March 31, 2026. The filing shows 1,524,907 shares of Common Stock with sole voting power and shared voting power of 369,088, representing 4.9% of the class.
The filing states 37,859,520 shares outstanding as of March 31, 2026. It also discloses 826,328 shares issuable upon exercise of options exercisable within 60 days and 5,684 RSUs vesting within 60 days. The report is signed by Chao in her capacity as President and CEO.
CeriBell, Inc. reported strong top-line growth but wider losses for the quarter ended March 31, 2026. Revenue rose 29% year over year to $26.5 million, driven evenly by product sales of Wearables at $20.2 million and subscription revenue of $6.3 million. Gross margin remained high at 87%, reflecting the scalable nature of its model.
Operating expenses increased 36% to $43.9 million, mainly from higher headcount across functions and significant legal spending tied to an intellectual property enforcement matter, leading to a net loss of $19.7 million versus $12.8 million a year earlier, or ($0.52) per share. EBITDA was a loss of $20.5 million, and Adjusted EBITDA, which excludes stock-based compensation and specified IP litigation costs, was a loss of $11.2 million.
CeriBell ended the quarter with $141.2 million in cash, cash equivalents, and marketable securities and $20.0 million of term debt outstanding. Management believes this liquidity, together with expected cash from customers, can fund planned operations and capital needs for at least the next 12 months.
Ceribell, Inc. reported strong first quarter 2026 growth but wider losses. Total revenue was $26.5 million, up 29% from $20.5 million a year earlier, driven by both product and subscription growth, and gross margin remained high at 87%. The company ended the quarter with 680 active accounts and launched neonate and pediatric products after a successful pilot. Net loss widened to $19.7 million, or $0.52 per share, compared with a $12.8 million loss, as operating expenses rose to $43.9 million on commercial investments, added headcount, and IP litigation costs. Adjusted EBITDA loss was $11.2 million. Ceribell held $141.2 million in cash, cash equivalents, and marketable securities as of March 31, 2026, and raised its 2026 revenue guidance to $112–$116 million, implying approximately 26%–30% growth over the prior year.
Ceribell, Inc. President and CEO Xingjuan Chao reported an exercise-and-sell transaction in Ceribell common stock. On May 5, 2026, she exercised stock options to acquire 25,000 shares at a conversion price of $4.70 per share and sold 39,000 shares in open-market trades at prices ranging from $19.77 to $20.48, based on weighted average prices. These trades were executed under a pre-arranged Rule 10b5-1 trading plan. Following the transactions, she holds 836,347 shares directly and 369,088 shares indirectly through the ACP 2021 Trust, where she serves as co-trustee and disclaims beneficial ownership beyond her pecuniary interest.
Ceribell Inc. ownership disclosure: FMR LLC reports beneficial ownership of 4,850,430.52 shares of Common Stock, representing 12.9% of the class, in an Amendment No. 3 to a Schedule 13G/A.
The filing states FMR LLC has 4,845,632 shares of sole voting power and 4,850,430.52 shares of sole dispositive power. The filing also notes that one or more other persons have rights to dividends or sale proceeds and refers to an attached 13d-1(k)(1) agreement.
Xingjuan Chao reports Rule 144 sales of Common stock. The filing lists sales of 2,084 shares on 02/23/2026 for $41,251.74, 39,000 shares on 03/03/2026 for $680,671.30, and 39,000 shares on 04/06/2026 for $717,550.46. The record also lists securities to be sold or exercised, including 39,000 shares associated with Fidelity Brokerage Services LLC and option-related entries dated 02/16/2023 and 09/25/2024.
Ceribell, Inc. Chief Technology Officer Raymond Woo reported an exercise-and-sell transaction in company stock. He exercised stock options covering a total of 11,104 shares of common stock at exercise prices of $4.70 and $2.24 per share, then sold 11,104 shares in open-market transactions at weighted average prices around $20.40 per share. According to the filing, these trades were carried out under a pre-arranged Rule 10b5-1 trading plan. Following the transactions, Woo directly holds 197,648 shares of Ceribell common stock.
CBLL submitted a Form 144 notice reporting proposed sales of Common Stock tied to option grants and recent open-market sales by Raymond Woo. The filing lists options granted on 07/07/2021 and 02/16/2023 with planned sales of 1,469 and 9,635 shares respectively, both with an 05/01/2026 sale date. The filing also discloses four sales by Raymond Woo during the prior three months: 11,112 shares on 02/02/2026 for $228,408.70, 705 shares on 02/23/2026 for $13,955.12, 11,112 shares on 03/02/2026 for $202,831.12, and 11,112 shares on 04/01/2026 for $206,260.79.